The key facts
- OpenAI acquired the startup Orchestra Bio; deal terms were not disclosed
- The startup had raised about $20 million from a16z, Atria, and 8VC (as of 2025)
- The team and technology will work on the Rosalind model and Rosalind Workbench
The deal and its terms
On Tuesday, October 20, 2026, OpenAI announced on its website the acquisition of the startup Orchestra Bio, which has been working at the intersection of AI and biotechnology for four years. The terms of the deal were not disclosed. According to available data, by 2025 the startup had raised about $20 million from investors including Andreessen Horowitz, Atria, and 8VC.
What Orchestra does
Orchestra develops AI agents that help biotech companies manage the operational details of the drug development process — from tracking finances to resolving scheduling issues with clinical trials.
What happens to the team and technology
OpenAI said that Orchestra's team and technology will be involved in work on Rosalind — an AI model for research in the life sciences — and on the related tool Rosalind Workbench, which is designed to help researchers plan experiments and analyze results. Among Rosalind's clients, OpenAI names Moderna and Novo Nordisk.
Context
TechCrunch notes that the deal is a characteristic example of how the largest AI labs, notably OpenAI and Anthropic, are building ever more software for the biggest industries, such as pharmaceuticals. There is a concern in the startup community that the labs could release new features at any moment and become competitors; in this case, Orchestra was acquired rather than pushed out of the market.
